Puma Biotechnology Inc · NASDAQ:PBYI
Puma Biotechnology — Q3 2021 Earnings Presentation
8 slides from Puma Biotechnology's earnings presentation, Nov 4, 2021
Slide 1: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update November 4 , 2021
Slide 2: Forward-Looking Safe-Harbor Statement
Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could ca
Slide 3: PUMA's Pharmacy and Distributor Network
PUMA’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network (SP) Acaria Health Accredo CVS ONCO 360 Patients Optum / Biologics Diplomat Sites of Care Specialty Distributor Network (SD) Academic Hospitals McKesson Community Hospitals ASD/Oncology Supply Physician Practices Cardina
Slide 4: ~$43 Million net NERLYNX revenue in Q3'21
~$43 Million net NERLYNX revenue in Q3’21 Quarterly Net Revenue (in $MM) 61.1 58.7 52.6 53.8 53.5 50.8 50.0 48.6 48.8 49.3 48.9 45.6 45.8 43.4 36.0 20.1 6.1 Copyright 2021 Puma Biotechnology 4
Slide 5: 2,947 Ex-factory bottles were sold in Q3'21
2,947 Ex-factory bottles were sold in Q3’21 Bottles Sold (SP + SD) by Quarter 5,538 4,936 4,935 4,799 4,791 4,696 4,452 4,035 3,728 3,611 3,517 3,585 3,247 3,354 2,947 2,137 675 Includes Commercial SP and SD Copyright 2021 Puma Biotechnology 5
Slide 6: ~57% of patients in Q3'21 started at a reduced dose
~57% of patients in Q3’21 started at a reduced dose* ** % of Patients starting at reduced dose 56.5% 42.4% 37.7% 38.7% 32.8% 30.4% 30.8% 28.4% 19.0% 12.0% 10.7% 6.3% 6.8% 2.9% 3.8% 1.8% 2.5% *Reduced dose defined as fewer than 6 pills per day ** FDA approved dose-escalation label supplement in June
Slide 7: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Region Partner Regulatory Approvals Commercial Launches • 2019 – Ext. Adj. in Australia, Singapore • 2020 – Singapore Australia / SE Asia • 2020 – Ext. Adj. in Brunei, Malaysia, New • Q2 2021 – Malaysia Zealand • Q3 / Q4 2021 – Brunei, New Zealand Israel • 2020
Slide 8: Puma Biotechnology
Puma Biotechnology Earnings Call Commercial Update November 4, 2021